Xeris Biopharma logo

Xeris Biopharma

XERS | NASDAQ
Chart Builder DCF Calculator
$16.70
+$0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET
$16.49
-$0.21 (-1.26%)
After-hours: Nov 16, 2026, 7:30 PM ET
+0.24%

Rating

Updated: Nov 16, 2026
51.4
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #254/1021 (Top 25%)

Key Statistics

Market Data

Market Cap $3.05B
1D Range
16.54 16.98
52W Range
5.29 16.98

Valuation (TTM)

PE -363.83
PB 62.54
EV/EBITDA 119.69

Valuation (NTM)

Forward PE 28,053.29
Forward PEG 22.47
Price Target $15.00
Loading financial charts...

Profile

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, n...

Sector Healthcare
Industry Biotechnology
Employees 435
IPO Date Jun 21, 2018
Fiscal Year January - December

Latest News

Xeris Biopharma: Time For A Pause

4 days ago · seekingalpha.com

Xeris Biopharma: Time For A Pause
Xeris Biopharma Q3 Earnings Call Highlights

10 days ago · marketbeat.com

Xeris Biopharma Q3 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

12 days ago · zacks.com

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100

24 days ago · gurufocus.com

Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

26 days ago · businesswire.com

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Lundbeck expresses interest in buying Xeris, Bloomberg News reports

2 months ago · reuters.com

Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

2 months ago · seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
Xeris Announces Details for XP-8121 Program Overview Webinar

3 months ago · businesswire.com

Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

3 months ago · seekingalpha.com

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.06
Beat +89.45%
REV
$107.23M
Beat +5.45%
Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$15.00
Downside
-10.18%
Buy (4)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.